DDrare: Database of Drug Development for Rare Diseases

167. マルファン症候群
［臨床試験数：19，薬物数：38（DrugBank：10），標的遺伝子数：10，標的パスウェイ数：49］

Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ATENOLOL; Aliskiren; Aprovel; Atenolol; Atenolol or Propranolol; BLOKIUM 50 mg comprimidos; Blokium 50; COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula; Coozar; Coversyl; Coversyl (perindopril); Cozaar; Cozaar 50; Doxycycline; Doxycycline 100-200mg capsules daily for 6 months; Doxycycline Hyclate Ph.Eur; Irbesartan; Irbesartan 150-300mg capsules daily for 6 months; LOBIVON*28CPR 5MG; LORTAAN*28CPR RIV DIV 50MG; LOSARTAN POTASSIUM; Lobivon; Lortaan; Losartan; Losartan Potassium; Losartan and Atenolol or Propranolol; Losartan and nebivolol; Losartan potassium; Nebivolol; PERINDOPRIL; Perindopril; Potassium; Propranolol; VERAPAMIL; Verapamil; Verapamil SR; Vibrox; Vibrox 100mg Capsules

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01949233 (ClinicalTrials.gov)	October 2013	6/8/2013	The Oxford Marfan Trial	A Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance Imaging	Marfan Syndrome	Drug: Irbesartan 150-300mg capsules daily for 6 months;Drug: Doxycycline 100-200mg capsules daily for 6 months;Drug: Doxycycline placebo capsules daily for 6 months;Drug: Irbesartan placebo capsules daily for 6 months	University of Oxford	Oxford University Hospitals NHS Trust	Recruiting	13 Years	N/A	Both	56	Phase 2	United Kingdom
2	EUCTR2010-023612-14-GB (EUCTR)	08/03/2013	20/12/2012	The Oxford Marfan Trial	A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0	Marfan syndrome. MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Clinical Trials and Research Governance	NULL	Not Recruiting			Female: yes Male: yes	56	Phase 2	United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01949233
(ClinicalTrials.gov)

October 2013

6/8/2013

The Oxford Marfan Trial

A Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance Imaging

Marfan Syndrome

Drug: Irbesartan 150-300mg capsules daily for 6 months;Drug: Doxycycline 100-200mg capsules daily for 6 months;Drug: Doxycycline placebo capsules daily for 6 months;Drug: Irbesartan placebo capsules daily for 6 months

University of Oxford

Oxford University Hospitals NHS Trust

Recruiting

13 Years

N/A

Both

Phase 2

United Kingdom

EUCTR2010-023612-14-GB
(EUCTR)

08/03/2013

20/12/2012

The Oxford Marfan Trial

A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0

Marfan syndrome.
MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Clinical Trials and Research Governance

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom